[go: up one dir, main page]

DE60122337D1 - Verwendung von taci als antitumormittel - Google Patents

Verwendung von taci als antitumormittel

Info

Publication number
DE60122337D1
DE60122337D1 DE60122337T DE60122337T DE60122337D1 DE 60122337 D1 DE60122337 D1 DE 60122337D1 DE 60122337 T DE60122337 T DE 60122337T DE 60122337 T DE60122337 T DE 60122337T DE 60122337 D1 DE60122337 D1 DE 60122337D1
Authority
DE
Germany
Prior art keywords
taci
antitumoring
agent
mammal
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60122337T
Other languages
English (en)
Other versions
DE60122337T2 (de
Inventor
Christine Ambrose
Jeffrey Thompson
Pascal Schneider
Paul Rennert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget Switzerland SA
Biogen Inc
Biogen MA Inc
Original Assignee
Apoxis SA
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoxis SA, Biogen Idec Inc, Biogen Idec MA Inc filed Critical Apoxis SA
Application granted granted Critical
Publication of DE60122337D1 publication Critical patent/DE60122337D1/de
Publication of DE60122337T2 publication Critical patent/DE60122337T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60122337T 2000-04-27 2001-04-27 Verwendung von taci als antitumormittel Expired - Lifetime DE60122337T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19994600P 2000-04-27 2000-04-27
US199946P 2000-04-27
PCT/US2001/040626 WO2001081417A2 (en) 2000-04-27 2001-04-27 Use of taci as an anti-tumor agent

Publications (2)

Publication Number Publication Date
DE60122337D1 true DE60122337D1 (de) 2006-09-28
DE60122337T2 DE60122337T2 (de) 2007-08-16

Family

ID=22739664

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60122337T Expired - Lifetime DE60122337T2 (de) 2000-04-27 2001-04-27 Verwendung von taci als antitumormittel

Country Status (13)

Country Link
EP (1) EP1297013B1 (de)
JP (1) JP2004513876A (de)
AT (1) ATE336509T1 (de)
AU (2) AU5392001A (de)
CA (1) CA2404945C (de)
CY (1) CY1105788T1 (de)
DE (1) DE60122337T2 (de)
DK (1) DK1297013T3 (de)
ES (1) ES2271004T3 (de)
NZ (1) NZ521629A (de)
PT (1) PT1297013E (de)
SI (1) SI1297013T1 (de)
WO (1) WO2001081417A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2261246A3 (de) 2000-08-18 2011-07-13 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU2002215753A1 (en) * 2000-12-07 2002-06-18 The University Of British Columbia Caml-binding peptides
EP1401870A4 (de) 2001-05-24 2006-04-19 Human Genome Sciences Antikörper gegen tumor necrosis factor delta (april)
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
EP2272868B1 (de) 2003-06-05 2015-03-04 Genentech, Inc. Kombinationstherapie für B-Zell-Erkrankungen
JP2008505607A (ja) 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2007019575A2 (en) * 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CA2651791A1 (en) 2006-05-15 2007-11-22 Ares-Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US11517591B2 (en) * 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
CN117736297A (zh) 2020-05-08 2024-03-22 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
EP1642972B1 (de) * 1999-01-07 2009-12-30 ZymoGenetics, Inc. Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon

Also Published As

Publication number Publication date
WO2001081417A2 (en) 2001-11-01
JP2004513876A (ja) 2004-05-13
ATE336509T1 (de) 2006-09-15
CA2404945A1 (en) 2001-11-01
EP1297013A2 (de) 2003-04-02
PT1297013E (pt) 2006-12-29
AU2001253920B2 (en) 2006-03-16
DE60122337T2 (de) 2007-08-16
SI1297013T1 (sl) 2007-06-30
ES2271004T3 (es) 2007-04-16
EP1297013B1 (de) 2006-08-16
CA2404945C (en) 2010-02-09
CY1105788T1 (el) 2011-02-02
WO2001081417A3 (en) 2002-06-20
DK1297013T3 (da) 2006-12-27
AU5392001A (en) 2001-11-07
NZ521629A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
DE60122337D1 (de) Verwendung von taci als antitumormittel
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
NO20060600L (no) Spesifikke bindingsmidler for hepatocytt vekstfaktorer
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
TR200102800T2 (tr) Yeni bileşikler.
ATE430589T1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
ES2153337T1 (es) Inhibidores de raf-quinasa.
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
BR0108046A (pt) Compostos azol condensados e seu uso como agentes hipoglicêmicos
SE0400208D0 (sv) Chemical compounds
EA200800889A1 (ru) Гексагидроциклооктилпиразольные каннабиноидные модуляторы
PT1067966E (pt) Composicao oftalmica compreendendo um bloqueador beta
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
BRPI0512310A (pt) compostos quìmicos
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
ES2097798T3 (es) Reactivo oxidable productor de color.
TR200000624T2 (tr) Bir enzimin etkinliğinin arttırılması ile ilgili bir yöntem.
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
DE60014048D1 (de) 1,5-anhydro-d-fruktose substituiert mit einer hydrophoben gruppe zur verwendung als antioxidant und/oder emulgator
DE69719218D1 (de) Verwendung von pvp oder povidone zum reduzieren von darmschwellungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN